Michael J. Topper

This paper shows that STING agonists combined with epigenetic drugs enhance necroptosis in TP53-mutated AML by activating STING and upregulating interferon-related genes.

The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.

This paper identifies EZH1-dependent H3K27me1 as an adaptive chromatin barrier limiting DNMT inhibitor response in colorectal cancer and shows that dual EZH1/2 inhibition synergizes with DNMTi to enhance therapeutic efficacy.

This study identifies that combining MYC inhibition with class IIa HDAC inhibition enhances mitochondrial dysfunction and reduces viability in NSCLC cell lines.

This study identifies ZNFX1 as a master regulator of epigenetically-induced pathogen mimicry and inflammasome signaling in ovarian cancer, linking its expression to disease progression and survival.